Figure 1.

CONSORT-like diagram for the analytic cohort obtained from the overall CanCORS cohort*. *The dotted line encases patients who were considered for this analysis. First-line therapy with bevacizumab was defined as receipt of bevacizumab within 8 weeks of starting any chemotherapy for stage IV or recurrent colorectal cancer (mCRC).

Zafar et al. BMC Cancer 2011 11:354   doi:10.1186/1471-2407-11-354
Download authors' original image